INmune Bio Inc. to Discuss Financial Outcomes for Q3 2024
INmune Bio Inc. (NASDAQ: INMB), a leader in clinical-stage research focusing on inflammation and immunology, plans to share its third-quarter financial results along with key corporate updates. This enlightening event will occur on October 31, 2024, at 4:30 PM Eastern Time, allowing stakeholders to get a comprehensive overview of the company's financial health and strategic direction.
Significance of the Upcoming Conference Call
As we approach the end of the quarter, the anticipation for INmune Bio's financial report is palpable. The management's ability to elucidate the results from the quarter ending September 30 will provide invaluable insight into how the company is navigating the complexities of the biotech landscape.
Interested parties are encouraged to dial in for the conference call approximately 5 to 10 minutes beforehand. Be sure to ask for the "INmune Bio Third Quarter Conference Call" when connecting with the operator. This live audio interaction promises to shed light on the latest developments within the company.
Conference Call Details
The logistics for the upcoming conference call are straightforward:
Date: October 31, 2024
Time: 4:30 PM ET
Dial-in Numbers: For domestic calls, use 1-800-343-4136. International participants can dial 1-203-518-9843.
Conference ID: INMUNE
A recording of the call will be available shortly after the event has concluded, with replays accessible until November 7, 2024. Investors and analysts alike can listen to the replay by calling 1-844-512-2921 for US callers or 1-412-317-6671 for international callers, using the PIN number 11157233 to access the playback.
About INmune Bio Inc.
INmune Bio Inc. is making significant strides in the biotechnology field by focusing on innovative therapies that leverage the innate immune system to combat serious health issues. They are actively engaged in clinical trials for two primary product platforms, targeting conditions such as Alzheimer’s Disease and various cancers.
The company's flagship product, XPRO, is in trials aimed at treating Mild Alzheimer’s disease through a novel approach involving dominant-negative technology to neutralize soluble TNF. This is one of several promising prospects designed to address urgent medical needs.
Treatment Approaches and Future Directions
In addition to Alzheimer’s, INmune Bio is exploring treatments for conditions like treatment-resistant depression and oncology through its Natural Killer Cell Priming Platform. The NK cell therapy, INKmune™, is currently undergoing a Phase I/II trial for men battling metastatic castrate-resistant prostate cancer, showcasing INmune's commitment to expanding its therapeutic reach.
As the company continues to innovate, the potential to venture into additional therapeutic areas underscores a commitment to delivering advanced treatment options, aiming to help countless patients affected by debilitating ailments.
Frequently Asked Questions
What is the date and time of INmune Bio's conference call?
The conference call is scheduled for October 31, 2024, at 4:30 PM Eastern Time.
How can I access the conference call?
To join the call, dial in using the numbers provided and reference Conference ID: INMUNE.
What is the main focus of INmune Bio Inc.?
INmune Bio focuses on developing therapies that activate the innate immune system to address various diseases, including Alzheimer's Disease.
What are the key products in INmune Bio's pipeline?
INmune Bio's primary products include XPRO for Alzheimer’s treatment and INKmune™ for cancer therapies.
Who can I contact for more information?
For inquiries, you can reach out to David Moss, CFO, at (858) 964-3720 or via email at info@inmunebio.com.
